Erasca reported preliminary efficacy data for its RAS-targeting oral drug ERAS-0015, reporting tumor shrinkage in 40% of patients with advanced pancreatic cancer and 62% of patients with advanced non-small cell lung cancer. The company said the results exceeded expectations, based on data collected from studies in the U.S. and China. The readouts arrive amid intensified competitive pressure following Revolution Medicines’ recent clinical update in advanced pancreatic cancer. Erasca’s disclosure also comes against a backdrop of legal escalation, with the company later stating it had received a legal threat from Revolution over patent and efficacy claims. Investors and clinicians will weigh whether ERAS-0015’s early signals translate into controlled trial endpoints and whether the competitive—possibly litigation-driven—environment affects development timelines.